menu
    • menu
    [{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Omega Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Financing","leadProduct":"Inapplicable","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"7","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Montai Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Evelo Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Public Offering","leadProduct":"EDP1815","moa":"||IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"8","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Evelo Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Private Placement","leadProduct":"EDP2939","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"8","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Senda Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series C Financing","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"4","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Abiologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"ProFound Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Ampersand Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Metaphore Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Flagship Pioneering \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Novo Nordisk"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Empress Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Cellarity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series C Financing","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flagship Pioneering \/ GSK","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ GSK"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Private Placement","leadProduct":"Tamibarotene","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"10","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2025","type":"Series B Financing","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Alltrna","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flagship Pioneering \/ Pfizer Inc","highestDevelopmentStatusID":"3","companyTruncated":"Flagship Pioneering \/ Pfizer Inc"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Flagship Pioneering \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Cystic Fibrosis Foundation"}]

    Find Clinical Drug Pipeline Developments & Deals by Flagship Pioneering

    Menu

    Flagship Pioneering

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Flagship And Pfizer To Discover Novel Autoimmune Inhibitors

                            Details : The collaboration aims to discover compounds which may lead to the development of next-generation therapeutics for autoimmune diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 01, 2025

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Discovery Platform

                            Recipient : Ampersand Biomedicines

                            Deal Size : $65.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Ampersand Biomedicines Raises Series B Financing and Highlights Pipeline Advancements

                            Details : The financing will be used for Ampersand's AND™ Platform to identify programmed biologics for the treatment of obesity-related targets.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 19, 2025

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Discovery Platform

                            Recipient : Ampersand Biomedicines

                            Deal Size : $65.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Discovery Platform

                            Recipient : ProFound Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Flagship Pioneering and ProFound Collaborate on First-in-Class Therapeutics for Obesity

                            Details : ProFound will deploy its proprietary ProFoundry Platform in collaboration with Pioneering Medicines' expertise to discover novel proteins and evaluate their therapeutic relevance for obesity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 06, 2024

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Discovery Platform

                            Recipient : ProFound Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Montai Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Flagship Announces Two New Agreements with Ampersand & Montai

                            Details : Under the collaboration, Montai's CONECTA™ AI platform will be used to identify small molecules directed to a potential Non-Small Cell Lung Cancer-related target.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 20, 2024

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Montai Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Discovery Platform

                            Recipient : Ampersand Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Flagship Pioneering Signs Two Agreements Under Pfizer Strategic Partnership

                            Details : Under the collaboration, Ampersand's AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 20, 2024

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Discovery Platform

                            Recipient : Ampersand Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Discovery

                            Sponsor : GSK

                            Deal Size : $7,200.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GSK becomes Flagship's latest partner in $7B biobucks respiratory, immunology pact

                            Details : The Flagship collaborates with GSK to discover and develop a portfolio of future transformational medicines and vaccines for the treatment of respiratory and immunology diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $150.0 million

                            July 29, 2024

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Discovery

                            Sponsor : GSK

                            Deal Size : $7,200.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Abiologics

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Flagship’s Abiologics sets sail with $50M for synthetic protein R&D

                            Details : The proceeds will advance company's platform and develop a diverse pipeline of medicines, Synteins, with an initial focus on oncology and immunology indications.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 23, 2024

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Abiologics

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EDP2939,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Recipient : Evelo Biosciences

                            Deal Size : $25.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Evelo Biosciences Closes $25.5 Million Private Placement

                            Details : The company intends to use the net proceeds to fund the completion of the Company’s ongoing Phase 2a trial of EDP2939, an investigational orally delivered and gut-restricted bacterial extracellular vesicle being developed for the treatment of moderate ...

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Undisclosed

                            December 07, 2023

                            Lead Product(s) : EDP2939,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Recipient : Evelo Biosciences

                            Deal Size : $25.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery Platform

                            Recipient : Alltrna

                            Deal Size : $109.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Alltrna Announces Series B Raise of $109 Million to Advance tRNA Medicines for Stop Codon Disease

                            Details : The financing will be used to advance the company's platform and first drug candidates towards the clinic for a first indication in Stop Codon Disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 08, 2023

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery Platform

                            Recipient : Alltrna

                            Deal Size : $109.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Discovery

                            Recipient : Empress Therapeutics

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Gene...

                            Details : The net proceeds will be used to support the development of Empress's proprietary Chemilogics™ product platform which creates potential small molecule medicines and the company's initial pipeline of drug candidates.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 21, 2023

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery

                            Recipient : Empress Therapeutics

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth